{
    "clinical_study": {
        "@rank": "93896", 
        "acronym": "CLL", 
        "arm_group": [
            {
                "arm_group_label": "Bendamustine Hydrochloride Injection", 
                "arm_group_type": "Experimental", 
                "description": "d1-d2,i.v.gtt, 100mg/m2/d, 28 days per cycle, at most 6 cycles."
            }, 
            {
                "arm_group_label": "Chlorambucil", 
                "arm_group_type": "Active Comparator", 
                "description": "d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC\u22654\u00d7109 /L at d12-d14 ); d1-d2, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles(if WBC\uff1c4\u00d7109 /L at d12-d14 );"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether bendamustine is effective in the treatment\n      of initial treatment of  Chronic Lymphocytic Leukemia (CLL)."
        }, 
        "brief_title": "Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Lymphocytic Leukemia", 
            "Leukemia", 
            "Neoplasms"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have a diagnosis of CLL;\n\n          -  No prior or no standard treatment for CLL;\n\n          -  Binet stage B, C or symptomatic stage A;\n\n          -  Needs treatment to control diseases;\n\n          -  (Eastern Cooperative Oncology Group)ECOG performance status \u2264 2\n\n          -  Life expectancy \u22653 months\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Patients were diagnosed with or treated for malignant tumors other than CLL\n             (including active central nervous system lymphoma) within one year prior to entering\n             the study\n\n          -  Transformation to Richter's syndrome, or prolymphocytic leukemia(PLL)\n\n          -  Autoimmune hemolytic anemia requiring glucocorticoid therapy\n\n          -  Autoimmune thrombocytopenia requiring glucocorticoid therapy\n\n          -  Alanine aminotransferase(ALT)\uff1e3 times upper limits of normal value, Aspartate\n             aminotransferase(AST)\uff1e3 times upper limits of normal value, Total bilirubin(TBIL)\uff1e2\n             times upper limits of normal value, serum creatinine\uff1e1.5 times upper limits of normal\n             value;\n\n          -  Other serious Concomitant diseases which affect participation of this\n             study(uncontrolled diabetes, gastric ulcer, cardiac and pulmonary diseases, at active\n             phases of autoimmune diseases;\n\n          -  Serious or uncontrolled infections;\n\n          -  Central nervous system dysfunction with clinical symptoms;\n\n          -  Patients received major surgery within 30 days prior to study entry;\n\n          -  Pregnant or lactating women\n\n          -  Allergic to study drug or mannitol\n\n          -  Participation in any other clinical trials within 3 months prior to study   entry"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "96", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657955", 
            "org_study_id": "RGN0117"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bendamustine Hydrochloride Injection", 
                "intervention_name": "Bendamustine Hydrochloride Injection", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Chlorambucil", 
                "intervention_name": "Chlorambucil", 
                "intervention_type": "Drug", 
                "other_name": "Leukeran"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chlorambucil", 
                "Nitrogen Mustard Compounds", 
                "Bendamustine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 3, 2012", 
        "link": {
            "url": "http://lanjin.cn"
        }, 
        "location": {
            "contact": {
                "last_name": "Lu G Qiu, M.D.", 
                "phone_ext": "+8602223909172"
            }, 
            "contact_backup": {
                "email": "yujj@lanjin.cn", 
                "last_name": "Jian J Yu, Master", 
                "phone": "+8615336402752"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China"
                }, 
                "name": "Hematologic hospital of Chinese academy of medical sciences"
            }, 
            "investigator": {
                "last_name": "Lu G Qiu, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients", 
        "overall_contact": {
            "last_name": "Lu G Qiu, M.D.", 
            "phone": "+86-02223909172"
        }, 
        "overall_contact_backup": {
            "email": "yujj@lanjin.cn", 
            "last_name": "Jian J Yu, Master", 
            "phone": "+86-15336402751"
        }, 
        "overall_official": {
            "affiliation": "Hematologic Hospital of Chinese Academy of Medical Sciences", 
            "last_name": "Lu G Qiu, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall response rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657955"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progress free survival(PFS)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Duration of Response (DR)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "measure": "Overall Survival(OS)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Shandong Lanjin Pharmaceuticals Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shandong Lanjin Pharmaceuticals Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}